EA201590244A1 - METHOD OF MAKING MEANS FOR THE TREATMENT OF TUBERCULOSIS - Google Patents

METHOD OF MAKING MEANS FOR THE TREATMENT OF TUBERCULOSIS

Info

Publication number
EA201590244A1
EA201590244A1 EA201590244A EA201590244A EA201590244A1 EA 201590244 A1 EA201590244 A1 EA 201590244A1 EA 201590244 A EA201590244 A EA 201590244A EA 201590244 A EA201590244 A EA 201590244A EA 201590244 A1 EA201590244 A1 EA 201590244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
treating tuberculosis
solution
tuberculosis
manufacturing
Prior art date
Application number
EA201590244A
Other languages
Russian (ru)
Other versions
EA028883B1 (en
Inventor
Мыкола Ивановыч ГУМЕНЮК
Наталия Мыколаивна ДЕРКАЧ
Original Assignee
Мыкола Ивановыч ГУМЕНЮК
Деркач Наталия Мыколаивна
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мыкола Ивановыч ГУМЕНЮК, Деркач Наталия Мыколаивна filed Critical Мыкола Ивановыч ГУМЕНЮК
Publication of EA201590244A1 publication Critical patent/EA201590244A1/en
Publication of EA028883B1 publication Critical patent/EA028883B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Abstract

Способ изготовления средства для лечения туберкулеза принадлежит к химико-фармацевтической промышленности и медицине, в частности к способам изготовления средств для лечения туберкулеза в виде растворов для инфузий. Способ изготовления средства для лечения туберкулеза включает такие действия, как растворение в воде динатриевой соли этилендиаминтетрауксусной кислоты и натрия сернистокислого безводного, последующее растворение натрия парааминосалицилата, доведение объема раствора до необходимого путем добавления воды, насыщение раствора азотом, добавление гидроксида натрия до получения необходимой величины рН раствора. Способ изготовления средства для лечения туберкулеза позволяет получить продукт, который имеет стабильность свойств и необходимый уровень качества средства для лечения туберкулеза в процессе его хранения в течение 1-1,5 лет при температурах, которые не отличаются от комнатных.A method of manufacturing an agent for treating tuberculosis belongs to the chemical and pharmaceutical industry and medicine, in particular to methods for producing an agent for treating tuberculosis in the form of solutions for infusions. A method of making an agent for treating tuberculosis includes actions such as dissolving the disodium salt of ethylenediaminetetraacetic acid and sodium anhydrous sulfuric acid in water, then dissolving sodium para-aminosalicylate, adjusting the solution to the required amount by adding water, saturating the solution with nitrogen, adding sodium hydroxide to obtain the required solution pH . A method of manufacturing an agent for treating tuberculosis makes it possible to obtain a product that has the stability of properties and the required level of quality of an agent for treating tuberculosis during its storage for 1-1.5 years at temperatures that do not differ from room temperature.

EA201590244A 2012-07-24 2013-07-22 Method for producing an agent for the treatment of tuberculosis EA028883B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
UAU201209117U UA74097U (en) 2012-07-24 2012-07-24 Method for manufacturing drug for treatment of tuberculosis
PCT/UA2013/000080 WO2014017999A1 (en) 2012-07-24 2013-07-22 Method for producing an agent for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
EA201590244A1 true EA201590244A1 (en) 2015-06-30
EA028883B1 EA028883B1 (en) 2018-01-31

Family

ID=49997650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590244A EA028883B1 (en) 2012-07-24 2013-07-22 Method for producing an agent for the treatment of tuberculosis

Country Status (6)

Country Link
AP (1) AP2015008271A0 (en)
BR (1) BR112015001674A2 (en)
EA (1) EA028883B1 (en)
RU (1) RU2015106365A (en)
UA (1) UA74097U (en)
WO (1) WO2014017999A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111265475B (en) * 2020-02-28 2024-01-02 天津金耀药业有限公司 Isoniazid injection and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233842A1 (en) * 1992-10-08 1994-04-14 Asta Medica Ag Mesna injection solutions
UA58983U (en) * 2010-11-15 2011-04-26 Наталья Николаевна Деркач Method for manufacturing composition for treating tuberculosis

Also Published As

Publication number Publication date
EA028883B1 (en) 2018-01-31
BR112015001674A2 (en) 2017-08-08
WO2014017999A1 (en) 2014-01-30
AP2015008271A0 (en) 2015-02-28
UA74097U (en) 2012-10-10
RU2015106365A (en) 2016-09-10

Similar Documents

Publication Publication Date Title
PE20130181A1 (en) PROCEDURE FOR THE PREPARATION OF 4- {4 - [({[4-CHLORO-3- (TRIFLUOROMETIL) PHENYL] AMINO} CARBONYL) AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND ITS MONOHYDRATE
JP2015145418A5 (en)
PL412787A1 (en) Macrophage-based aimed system for delivery of ferritin related compounds
UA113981C2 (en) Ophthalmic solution containing diquafasol
GB2500128A (en) Colonoscopy-preparation
MX2015016424A (en) Aqueous solutions containing a complexing agent in high concentration.
MX2015016057A (en) Stabilized hypochlorous acid solution and use thereof.
PH12016500913A1 (en) Soap bar
EA201590244A1 (en) METHOD OF MAKING MEANS FOR THE TREATMENT OF TUBERCULOSIS
MX2013003581A (en) Process for producing granules comprising one or more complexing agent salts.
EA201391595A1 (en) NEW METALLOPROTEIN, METHOD FOR ITS OBTAINING AND PROPHYLACTIC OR THERAPEUTIC AGENT IN HYDROUS DISEASES OR CONJUNCTION CONTAINING METABLE PROTEIN
PL420099A1 (en) Method for production of alpha-ketoglutaric acid (AKG) from one-component water solutions
EA201491767A1 (en) METHOD AND INSTALLATION FOR THE PRODUCTION OF SOLUTIONS OF NONLINK AGENTS
RU2013152987A (en) METHOD FOR PRODUCING TETRACHLOROPLOATE (II) -ION ION AND ITS SALTS WITH SODIUM, POTASSIUM OR AMMONIUM
RU2013107097A (en) METHOD FOR PRODUCING CIS-Dichlorodiammine Platinum (II)
UA105830C2 (en) Method for the preparation of agent for tuberculosis treatment and agent prepared by the method
PL410425A1 (en) New alkoxymethyl di(2-hydroxyethyl)methylammonium ionic liquids with sweet anion and method for producing them
RU2013133363A (en) METHOD FOR PREVENTION OF DAMAGE TO BIOLOGICAL MEMBRANES
CL2010000178A1 (en) Method to favor the production of extracellular polymeric substances (eps) in a culture of acidithiobacillus ferrooxidans, based on inhibiting the enzymes citrate synthetase, aconitase and / or isocitrate dehydrogenase of the tricarboxylic acid cycle.
PL400503A1 (en) Method for producing alkali metal salts of 2,3-dihydroxypropanesulfonic acid
RU2014114107A (en) METHOD FOR PRODUCING COLLOIDAL SOLUTION OF LEAD SULPHIDE NANOPARTICLES
FI20105036A0 (en) Process for preparing a carbamate cellulose solution
RU2013152580A (en) METHOD FOR OBTAINING ADEMETHIONINE DOUBLE SALT WITH SULFUR AND N-TOLUOLSULFO ACID
RU2011153118A (en) METHOD FOR PRODUCING ANTIBACTERIAL POLYMERIC MEMBRANE
UA91463C2 (en) Method for the production of calcium nitrate

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU